Zanubrutinib plus BR for first treatment of Waldenström's macroglobulinemia
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study is testing a combination of two medicines (zanubrutinib and BR) as the first treatment for patients with Waldenström's macroglobulinemia. The goal is to see if this combination works well and is safe for people who have not been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have not received any treatment for your Waldenström's macroglobulinemia yet and you have symptoms.
- You have a diagnosis of Waldenström's macroglobulinemia confirmed by specific blood and bone marrow tests.
- Your blood has a certain protein (IgM) level of at least 5 grams per liter.
- You have a specific gene change called MYD88 L265P in your blood or bone marrow.
- You do not have other active cancers, uncontrolled infections, or serious heart, liver, kidney, or digestive problems.
- You have adequate blood cell counts and organ function (like liver and kidneys).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study combines a targeted pill (zanubrutinib) with a lower dose of a chemotherapy drug (bendamustine) and an antibody treatment to see if it works well for people with untreated Waldenström's macroglobulinemia. It aims to reduce side effects while still controlling the disease.
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
This trial tests a combination of three drugs (zanubrutinib, bendamustine, and rituximab) for people with Waldenstrom macroglobulinemia who have not been treated before. The goal is to see if this combination is safe and effective.
This is an observational study that follows people with Waldenström macroglobulinemia (WM) to learn how well zanubrutinib works and how safe it is. Your results will be tracked in relation to your disease features, including a blood/marrow marker called MYD88.
This study tests a new approach for people with Waldenström macroglobulinemia who have already been on ibrutinib and are doing well but not completely better. It adds two more medicines (bendamustine and rituximab) to see if this combination can achieve a deeper response and allow you to stop treatment after a set period.
This study tests a combination of two oral medications (zanubrutinib and BGB-11417) for people with Waldenström macroglobulinemia that has returned or not improved after prior therapy. The goal is to see if this combination is safe and works better at controlling the disease.
Hear when a new Waldenström's Macroglobulinemia (WM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.